The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials

Abstract

BackgroundDespite the fact that obesity and overweight are serious major health problems worldwide, fighting against them is also considered a challenging issue. Several interventional studies have evaluated the potential weight-reduction effect of Tirzepatide. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of subcutaneous Tirzepatide on obesity and overweight.MethodsScopus, PubMed/Medline, Web of Science, Cochrane, and Embase databases were searched using standard keywords to identify all controlled trials investigating the weight loss effects of Tirzepatide. Pooled weighted mean difference and 95% confidence intervals were achieved by random-effects model analysis for the best estimation of outcomes. The statistical heterogeneity and publication bias were determined using the Cochran’s Q test and I2 statistics and using the funnel plot and Egger’s test, respectively.ResultsTwenty three treatments arm with 7062 participants’ were included in this systematic review and meta‐regression analysis. The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001). These reductions were even greater, especially with higher doses and duration of Tirzepatide.ConclusionsTirzepatide medication had significant effects on weight management with the reduction of body weight, BMI, and WC. Administration of Tirzepatide can be considered a therapeutic strategy for overweight or obese people.

Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks

“…24 A systematic review and meta-analysis included 7062 participants and pooled findings showed significant body weight, BMI, and waist circumference reduction with tirzepatide compared to placebo. 96…”

“…However, SURMOUNT trials have focused on studying tirzepatide and obesity and showed significant and sustained weight loss up to 20.9% mean change in body weight at 15 mg, compared to placebo 24 . A systematic review and meta‐analysis included 7062 participants and pooled findings showed significant body weight, BMI, and waist circumference reduction with tirzepatide compared to placebo 96 …”

Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses

“…Another, meta-regression analysis was done by Rohani et al, on the effect of Tirzepatide on body weight. In congruence with other studies, here also, the overall findings showed a significant reduction in body weight (-11.34 kg [-12.79 to -9.88] P<0.001), body mass index (-3.11 [-4.36 to -1.86] kg/m 2 , P<0.001), and waist circumference (-7.24 [-10.12 to -4.36] cm, P< 0.001) [ 28 ]. A meta-analysis was published on the safety of Tirzepatide by Zeng Q et al, in October 2023, whereby, Tirzepatide was not found to be significantly associated with an increased risk of pancreatitis when compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo (RR 1.46, [95% CI] 0.59 to 3.61; I2 = 0.0%, p = 0.436).…”

Newer pharmacological interventions directed at gut hormones for obesity

“…Three systematic reviews and meta-analyses have been published in 2023, documenting the weight loss benefits of tirzepatide (Lin et al, 2023;Rohani et al, 2023;Tan et al, 2023), with one drawing attention to the need for vigilance regarding gastrointestinal adverse effects (Lin et al, 2023).…”